En Es
Categorías

Shenzhen YHLO Biotech Co., Ltd.

Shenzhen YHLO Biotech Co., Ltd. (YHLO) is an immunoassay solutions company that specializes in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents with own intellectual properties. Based on the technology platforms of chemiluminescence (CLIA), monotest ELISA, line immunoblot, immunofluorescenc ...
Miembro Oro
Productos Covid-19Resumen
Close

Covid-19 Shenzhen YHLO Biotech Co., Ltd.

Laboratorio clínico

SARS-CoV-2 IgM & IgG CLIA Assays
iFlash 3000 / iFlash 1800 / iModules

YHLO’s IgG and IgM combined detection is a good supplementary diagnostic tool to PCR, which can identify who are immune to COVID-19 after infection in mass population and its titer change can be used to monitor treatment of COVID-19 patients. Together with iFlash fully automation system, manual work and aerosol contamination risk can be reduced. The assays are CE marked, FDA EUA application accepted and legal export qualification obtained.
Mas detalles
Close

Sobre Shenzhen YHLO Biotech Co., Ltd.

Shenzhen YHLO Biotech Co., Ltd. (YHLO) is an immunoassay solutions company that specializes in developing, manufacturing and distributing in-vitro diagnostic instruments and reagents with own intellectual properties. Based on the technology platforms of chemiluminescence (CLIA), monotest ELISA, line immunoblot, immunofluorescence, YHLO has developed hundreds of test items on autoimmunity, reproductive health, diabetes, infection and routine immunochemistry. YHLO is one of the very few suppliers in China for autoimmune instruments and reagents, and has launched China`s first monotest ELISA analyzer – UNION, China`s first ESR analyzer with direct EDTA tube testing – VISION, China`s first high-speed Chemiluminescence System - iFlash 3000 CLIA System (300 T/H), and China`s first autoimmune assays in CLIA, LIA and ELISA platforms. YHLO has also launched Anti-Müllerian Hormone (AMH) dedicated to ELISA and CLIA systems, as well as the world`s first CLIA assays for Inhibin B, Adiponectin, ZnT8A, RA33, etc. In 2020, YHLO launched CLIA assays of SARS-CoV-2 IgM and IgG to aid the diagnosis of COVID-19.
Facebook Twitter Google+ Linked in
SARS-CoV-2 IgM & IgG CLIA Assays

SARS-CoV-2 IgM & IgG CLIA Assays

Modelo: iFlash 3000 / iFlash 1800 / iModules
Solicite información

Descripción:

YHLO’s IgG and IgM combined detection is a good supplementary diagnostic tool to PCR, which can identify who are immune to COVID-19 after infection in mass population and its titer change can be used to monitor treatment of COVID-19 patients. Together with iFlash fully automation system, manual work and aerosol contamination risk can be reduced.
Más info

Descripción completa

Descripción

YHLO’s IgG and IgM combined detection is a good supplementary diagnostic tool to PCR, which can identify who are immune to COVID-19 after infection in mass population and its titer change can be used to monitor treatment of COVID-19 patients. Together with iFlash fully automation system, manual work and aerosol contamination risk can be reduced. The assays are CE marked, FDA EUA application accepted and legal export qualification obtained. Solicite información

Enviar un mensaje al proveedor

* Información requerida
* Email:
Para
Shenzhen YHLO Biotech Co., Ltd. ()
* Mensaje

Derecho de autor © 2000-2020 TradeMed.com. Todos los derechos reservados. | Términos y condiciones